|
|
|
| Advances in the study of neuromyelitis optic spectrum disease |
| WANG Chunchen1 CHEN Zhigang2▲ WANG Hong1 LI Bin1 XING Yi3 WANG Guiling1 LIU Chunhong4 |
1.Center of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China;
2.Department of Neurology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China;
3.Department of Neurology, Xuanwu Hospital Capital Medical University, Beijing 100053, China;
4.Key Laboratory of Acupuncture and Moxibustion Neuromodulation, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China |
|
|
|
Abstract Neuromyelitis optica is an inflammatory demyelinating disease of central nervous system involving the optic nerve and spinal cord. As a demyelinating disease of the central nervous system, it has high incidence in Asia. It has high recurrence rate, severe clinical symptoms and poor prognosis, which affect the life quality of patients seriously. Recently, it has become a hot topic in the study of neuroimmunology area. In this paper, we summarize and analyze the characteristics, epidemiology, pathophysiological basis, clinical manifestation, diagnostic evaluation, diagnostic criteria, differential diagnosis, acute stage treatment, prevention of attack treatment and prognosis of the disease, in order to provide ideas for clinical diagnosis and further scientific research.
|
|
|
|
|
|
[1] Uzawa A，Mori M，Kuwabara S. Neuromyelitis optica：concept，immunology and treatment [J]. J Clin Neurosci，2014， 21（1）：12-21.
[2] Asgari N，Lillevang ST，Skejoe HP，et al. A population-based study of neuromyelitis optica in Caucasians [J]. Neurology，2011，76（18）：1589-1595.
[3] Flanagan EP，Cabre P，Weinshenker BG，et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum [J]. Ann Neurol，2016，79（5）：775-783.
[4] Mealy MA，Wingerchuk DM，Greenberg BM，et al. Epidemiology of neuromyelitis optica in the United States：a multicenter analysis [J]. Arch Neurol，2012，69（9）：1176-1180.
[5] Cabrera-Gómez JA，Kurtzke JF，Gonzalez-Quevedo A，et al. An epidemiological study of neuromyelitis optica in Cuba [J]. J Neurol，2009，256（1）：35-44.
[6] Sellner J，Boggild M，Clanet M，et al. EFNS guidelines on diagnosis and management of neuromyelitis optica [J]. Eur J Neurol，2010，17（8）：1019-1032.
[7] Confavreux C，Vukusic S. The clinical epidemiology of multiple sclerosis [J]. Neuroimaging Clin N Am，2008，18（4）：589-622，ix-x.
[8] Wang H，Dai Y，Qiu W，et al. HLA-DPB1 0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in southern Han Chinese [J]. J Neuroimmunol，2011，233（1/2）：181-184.
[9] Brum DG，Barreira AA，dos Santos AC，et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis [J]. Mult Scler，2010，16（1）：21-29.
[10] Kim HJ，Park HY，Kim E，et al. Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica [J]. Neurobiol Dis，2010，37（2）：349-355.
[11] Liu C，Wang G，Liu H，et al. CD226 Gly307Ser association with neuromyelitis optica in Southern Han Chinese [J]. Can J Neurol Sci，2012，39（4）：488-490.
[12] Zhao GX，Liu Y，Li ZX，et al. Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population [J]. Neurosci Bull，2013，29（5）：525-530.
[13] Takahashi T，Fujihara K，Nakashima I，et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO：a study on antibody titre [J]. Brain，2007，130（Pt 5）：1235-1243.
[14] Steelman AJ. Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation [J]. Front Immunol，2015，6：520.
[15] Chihara N，Aranami T，Sato W，et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica [J]. Proc Natl Acad Sci U S A，2011，108（9）：3701-3706.
[16] Papadopoulos MC，Verkman AS. Aquaporin 4 and neuromyelitis optica [J]. Lancet Neurol，2012，11（6）：535-544.
[17] Wingerchuk DM，Banwell B，Bennett JL，et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders [J]. Neurology，2015，85（2）：177-189.
[18] Wingerchuk DM，Hogancamp WF，O'Brien PC，et al. The clinical course of neuromyelitis optica（Devic′s syndrome）[J]. Neurology，1999，53（5）：1107-1114.
[19] Beh SC，Greenberg BM，Frohman T，et al. Transverse myelitis [J]. Neurol Clin，2013，31（1）：79-138.
[20] Nakamura M，Miyazawa I，Fujihara K，et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study [J]. J Neurol，2008，255（2）：163-170.
[21] Araki M，Matsuoka T，Miyamoto K，et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica：a pilot study [J]. Neurology，2014，82（15）：1302-1306.
[22] Kupersmith MJ，Alban T，Zeiffer B，et al. Contrast-enhanced MRI in acute optic neuritis：relationship to visual performance [J]. Brain，2002，125（Pt 4）：812-822.
[23] Kremer L，Mealy M，Jacob A，et al. Brainstem manifestations in neuromyelitis optica：a multicenter study of 258 patients [J]. Mult Scler，2014，20（7）：843-847.
[24] Fryer JP，Lennon VA，Pittock SJ，et al. AQP4 autoantibody assay performance in clinical laboratory service [J]. Neurol Neuroimmunol Neuroinflamm，2014，1（1）：e11.
[25] Jarius S，Aboul-Enein F，Waters P，et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica [J]. Brain，2008，131（Pt 11）：3072-3080.
[26] Pellkofer HL，Krumbholz M，Berthele A，et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab [J]. Neurology，2011，76（15）：1310-1315.
[27] Trebst C，Jarius S，Berthele A，et al. Update on the diagnosis and treatment of neuromyelitis optica：recommendations of the Neuromyelitis Optica Study Group （NEMOS）[J]. J Neurol，2014，261（1）：1-16.
[28] McDonald WI，Compston A，Edan G，et al. Recommended diagnostic criteria for multiple sclerosis：guidelines from the International Panel on the diagnosis of multiple sclerosis [J]. Ann Neurol，2001，50（1）：121-127.
[29] Kimbrough DJ，Fujihara K，Jacob A，et al. Treatment of Neuromyelitis Optica：Review and Recommendations [J]. Mult Scler Relat Disord，2012，1（4）：180-187.
[30] Kim SH，Huh SY，Lee SJ，et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder [J]. JAMA Neurol，2013，70（9）：1110-1117.
[31] Collongues N，de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica [J]. Ther Adv Neurol Disord，2016，9（3）：180-188.
[32] Montcuquet A，Collongues N，Papeix C，et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG，MOG-IgG，and seronegative neuromyelitis optica spectrum disorders [J]. Mult Scler，2017，23（10）：1377-1384.
[33] Collongues N，de Seze J. Current and future treatment approaches for neuromyelitis optica [J]. Ther Adv Neurol Disord，2011，4（2）：111-121.
[34] Cabre P，Olindo S，Marignier R，et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum：clinical and neuroradiological study [J]. J Neurol Neurosurg Psychiatry，2013，84（5）：511-516.
[35] Pittock SJ，Lennon VA，McKeon A，et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders：an open-label pilot study [J]. Lancet Neurol，2013，12（6）：554-562.
[36] Kieseier BC，Stuve O，Dehmel T，et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica：implication for cellular immune responses [J]. JAMA Neurol，2013，70（3）：390-393.
[37] Krampla W，Aboul-Enein F，Jecel J，et al. Spinal cord lesions in patients with neuromyelitis optica：a retrospective long-term MRI follow-up study [J]. Eur Radiol，2009，19（10）：2535-2543.
[38] Ringelstein M，Ayzenberg I，Harmel J，et al. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder [J]. JAMA Neurol，2015，72（7）：756-763.
[39] Tradtrantip L，Zhang H，Saadoun S，et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica [J]. Ann Neurol，2012，71（3）：314-322.
[40] Kleiter I，Gahlen A，Borisow N，et al. Neuromyelitis optica：Evaluation of 871 attacks and 1，153 treatment courses [J]. Ann Neurol，2016，79（2）：206-216.
[41] Wingerchuk DM，Weinshenker BG. Neuromyelitis optica： clinical predictors of a relapsing course and survival [J]. Neurology，2003，60（5）：848-853. |
|
|
|
